

BIOTECHNEWS

THE LETTER DEDICATED TO LIFE SCIENCES DECISION MAKERS

FEBRUARY 2013

ONE LETTER = ONE PLAYER or ONE DEAL pushed by email to > 209 500 key professionals

PRESS RELEASE

A \$470 MILLIONS LICENSING DEAL : CROSSJECT SIGNED A MAJOR DEVELOPMENT & COMMERCIAL PARTNERING DEAL

CHENOVE - FRANCE, February 2013

\$ 470 MILLIONS : CROSSJECT SIGNED A MAJOR WORLDWIDE PARTNERING DEAL IN Q1-2013 ON A VERY FAST GROWING THERAPEUTIC MARKET. This new deal is following our previous announcement of another partnering deal signed in Q3-2012 on rheumatoid arthritis.

Under the terms of the agreement, CROSSJECT will receive \$12 millions in upfront & milestones payments before 2015, as well as + \$460 millions in transfer margin of the drug and double digit royalties. The European pharmaceutical partner will use CROSSJECT true needle-free injection system called ZENEO to develop several new pre-filled & disposable auto-injectors in order to reach a market approval in early 2015 targeting a very fast growing market promising to reach +2 billions dollars in 2020.

According to Patrick Alexandre, Crossject CEO, "this major partnering deal is the recognition of our 10 years development program on this disposable technology started in 1998 inside Fournier laboratories with SNPE supports, including as well our several key partnerships like GSK, ABBOTT, NOVAGALI. By the way, we would like to thank our shareholders and their active supports during the last ten years. These partnerships gave us the capacity to deliver now to the market **the sole and unique , true** needle free injection system able to deliver drugs through 3 routes : subcutaneous, intradermic and **intramuscular**"

According to Philippe Monnot and Thierry Garret, both co-founder of Gemmes Ventures, the historical fund and main shareholder of Crossject : " No worldwide innovation can take root overnight. Gemmes Venture is supporting Crossject since 10 years and our enthusiasm remains as before. Thus we will not hesitate to go all the way through this great medtech adventure, full of human encounters. We will be very proud when our children will use Zeneo device from Crossject within the next few years "


NEXT STEP : This major milestones needs now to be complete by a new financing round in order to ramp up the manufacturing capacity of Crossject in France. SCIENTEX, a transition management firm dedicated to life sciences SMEs, primarily in charge of the day to day corporate and business development of CROSSJECT, will organize this new financing by targeting European private equity & family offices.



You can download several video presenting Zeneo and CROSSJECT fact sheet under the following link:

- <http://www.scientex.eu/resources/D%C3%A9mo+ZENEO.wmv>
- <http://www.scientex.eu/resources/Crossject+FILM-.wmv>
- <http://www.scientex.eu/resources/How+to+Use+ZENEO.wmv>
- <http://www.scientex.eu/resources/Plaqueette+CROSSJECT.pdf>

Size of ZENEO in Inches: 3 X 2 X 1,1



• **Contacts for partnering with Crossject**

Companies interested in partnering with CROSSJECT; regarding the use of its disposable and true needle-free auto-injection system ZENEO®; are welcome to contact Dr. Tim MULLER, managing marketing, partnering, business & corporate development affairs at CROSSJECT in its role of Chief Business Officer.



Contacts for participating in Crossject next financing round

Due to the private equity background of CROSSJECT's CBO; Tim MULLER, founder of SCIENTEX, is as well managing the fundraising. Investors are welcome to contact Dr. Tim MULLER – Chief Business Officer - email : tm@scientex.eu or t.muller@crossject.com - Mobile : +33 (0) 645 523 540 (main) or +33 (0) 602 510 791 (secondary) - Office phone : +33 (0)977 1956 79

About CROSSJECT :

60L avenue du 14 juillet 21300 CHENOVE – France

Mr Patrick Alexandre, CEO

Mobile: +33 (0) 671 909 077

p.alexandre@crossject.com

<http://www.crossject.com>

[Click here to contact CROSSJECT](#)



About SCIENTEX:


From science to stock exchange

SCIENTEX is a french advisory, interim & transition management firm, fully dedicated to European life sciences SMEs.

Scientex founder's is acting as an executive sherpa for C-level managers; offering 4 global & integrated operational supports for their corporate affairs.

<http://www.scientex.eu>

[Click here to download Scientex's fact sheet](#)



About BIOTECHNEWS:

BIOTECHNEWS is an independent, private, worldwide, life sciences letter with an unique concept: *one letter = one player or one deal*

BIOTECH NEWS is now delivered to +205 900 key life sciences professionals including 50% of board members, VP-level & C-level managers. Thanks to an IP partnership, all SCIENTEX's clients have access to worldwide corporate communication campaigns pushed by BIOTECHNEWS. **Your contact covering Europe : br@biotechnews.fr**